Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,786
archived clinical trials in
Dermatology

A Study to Evaluate the Effectiveness and Safety of a Topical Ointment to Treat Subjects With Atopic Dermatitis
A Phase 2 Multi-center, Randomized, Double-blind, Vehicle-controlled, Three-arm, Parallel Group Study to Assess the Safety, Tolerability, and Efficacy of Topical OPA-15406 Ointment, in Subjects With Mild/Moderate Atopic Dermatitis
Status: Enrolling
Updated:  1/28/2016
Clinical Research Facility
mi
from
College Station, TX
A Study to Evaluate the Effectiveness and Safety of a Topical Ointment to Treat Subjects With Atopic Dermatitis
A Phase 2 Multi-center, Randomized, Double-blind, Vehicle-controlled, Three-arm, Parallel Group Study to Assess the Safety, Tolerability, and Efficacy of Topical OPA-15406 Ointment, in Subjects With Mild/Moderate Atopic Dermatitis
Status: Enrolling
Updated: 1/28/2016
Clinical Research Facility
mi
from
College Station, TX
Click here to add this to my saved trials
A Study to Evaluate the Effectiveness and Safety of a Topical Ointment to Treat Subjects With Atopic Dermatitis
A Phase 2 Multi-center, Randomized, Double-blind, Vehicle-controlled, Three-arm, Parallel Group Study to Assess the Safety, Tolerability, and Efficacy of Topical OPA-15406 Ointment, in Subjects With Mild/Moderate Atopic Dermatitis
Status: Enrolling
Updated:  1/28/2016
Clinical Research Facility
mi
from
Houston, TX
A Study to Evaluate the Effectiveness and Safety of a Topical Ointment to Treat Subjects With Atopic Dermatitis
A Phase 2 Multi-center, Randomized, Double-blind, Vehicle-controlled, Three-arm, Parallel Group Study to Assess the Safety, Tolerability, and Efficacy of Topical OPA-15406 Ointment, in Subjects With Mild/Moderate Atopic Dermatitis
Status: Enrolling
Updated: 1/28/2016
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
A Study to Evaluate the Effectiveness and Safety of a Topical Ointment to Treat Subjects With Atopic Dermatitis
A Phase 2 Multi-center, Randomized, Double-blind, Vehicle-controlled, Three-arm, Parallel Group Study to Assess the Safety, Tolerability, and Efficacy of Topical OPA-15406 Ointment, in Subjects With Mild/Moderate Atopic Dermatitis
Status: Enrolling
Updated:  1/28/2016
Clinical Research Facility
mi
from
San Antonio, TX
A Study to Evaluate the Effectiveness and Safety of a Topical Ointment to Treat Subjects With Atopic Dermatitis
A Phase 2 Multi-center, Randomized, Double-blind, Vehicle-controlled, Three-arm, Parallel Group Study to Assess the Safety, Tolerability, and Efficacy of Topical OPA-15406 Ointment, in Subjects With Mild/Moderate Atopic Dermatitis
Status: Enrolling
Updated: 1/28/2016
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study to Evaluate the Effectiveness and Safety of a Topical Ointment to Treat Subjects With Atopic Dermatitis
A Phase 2 Multi-center, Randomized, Double-blind, Vehicle-controlled, Three-arm, Parallel Group Study to Assess the Safety, Tolerability, and Efficacy of Topical OPA-15406 Ointment, in Subjects With Mild/Moderate Atopic Dermatitis
Status: Enrolling
Updated:  1/28/2016
Clinical Research Facility
mi
from
Norfolk, VA
A Study to Evaluate the Effectiveness and Safety of a Topical Ointment to Treat Subjects With Atopic Dermatitis
A Phase 2 Multi-center, Randomized, Double-blind, Vehicle-controlled, Three-arm, Parallel Group Study to Assess the Safety, Tolerability, and Efficacy of Topical OPA-15406 Ointment, in Subjects With Mild/Moderate Atopic Dermatitis
Status: Enrolling
Updated: 1/28/2016
Clinical Research Facility
mi
from
Norfolk, VA
Click here to add this to my saved trials
A Study to Evaluate the Effectiveness and Safety of a Topical Ointment to Treat Subjects With Atopic Dermatitis
A Phase 2 Multi-center, Randomized, Double-blind, Vehicle-controlled, Three-arm, Parallel Group Study to Assess the Safety, Tolerability, and Efficacy of Topical OPA-15406 Ointment, in Subjects With Mild/Moderate Atopic Dermatitis
Status: Enrolling
Updated:  1/28/2016
Clinical Research Facility
mi
from
Spokane, WA
A Study to Evaluate the Effectiveness and Safety of a Topical Ointment to Treat Subjects With Atopic Dermatitis
A Phase 2 Multi-center, Randomized, Double-blind, Vehicle-controlled, Three-arm, Parallel Group Study to Assess the Safety, Tolerability, and Efficacy of Topical OPA-15406 Ointment, in Subjects With Mild/Moderate Atopic Dermatitis
Status: Enrolling
Updated: 1/28/2016
Clinical Research Facility
mi
from
Spokane, WA
Click here to add this to my saved trials
A Study to Evaluate the Effectiveness and Safety of a Topical Ointment to Treat Subjects With Atopic Dermatitis
A Phase 2 Multi-center, Randomized, Double-blind, Vehicle-controlled, Three-arm, Parallel Group Study to Assess the Safety, Tolerability, and Efficacy of Topical OPA-15406 Ointment, in Subjects With Mild/Moderate Atopic Dermatitis
Status: Enrolling
Updated:  1/28/2016
Clinical Research Facility
mi
from
Los Angeles, CA
A Study to Evaluate the Effectiveness and Safety of a Topical Ointment to Treat Subjects With Atopic Dermatitis
A Phase 2 Multi-center, Randomized, Double-blind, Vehicle-controlled, Three-arm, Parallel Group Study to Assess the Safety, Tolerability, and Efficacy of Topical OPA-15406 Ointment, in Subjects With Mild/Moderate Atopic Dermatitis
Status: Enrolling
Updated: 1/28/2016
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Tolerance Evaluation of a Nighttime Moisturizing Balm on Babies and Adults With Eczema
Clinical Trial to Evaluate the Tolerance of a Nighttime Moisturizing Balm on Babies and Adults With Mild to Moderate Atopic Dermatitis
Status: Enrolling
Updated:  2/3/2016
Hill Top Research
mi
from
St. Petersburg, FL
Tolerance Evaluation of a Nighttime Moisturizing Balm on Babies and Adults With Eczema
Clinical Trial to Evaluate the Tolerance of a Nighttime Moisturizing Balm on Babies and Adults With Mild to Moderate Atopic Dermatitis
Status: Enrolling
Updated: 2/3/2016
Hill Top Research
mi
from
St. Petersburg, FL
Click here to add this to my saved trials
Tolerance Evaluation of a Nighttime Moisturizing Balm on Babies and Adults With Eczema
Clinical Trial to Evaluate the Tolerance of a Nighttime Moisturizing Balm on Babies and Adults With Mild to Moderate Atopic Dermatitis
Status: Enrolling
Updated:  2/3/2016
TKL research
mi
from
Fair Lawn, NJ
Tolerance Evaluation of a Nighttime Moisturizing Balm on Babies and Adults With Eczema
Clinical Trial to Evaluate the Tolerance of a Nighttime Moisturizing Balm on Babies and Adults With Mild to Moderate Atopic Dermatitis
Status: Enrolling
Updated: 2/3/2016
TKL research
mi
from
Fair Lawn, NJ
Click here to add this to my saved trials
Photocil (Topical) for the Treatment of Vitiligo
Pilot Study of Novel Topical Drug (Photocil) for the Treatment of Vitiligo
Status: Enrolling
Updated:  2/12/2016
Physicians Institute
mi
from
Tucson, AZ
Photocil (Topical) for the Treatment of Vitiligo
Pilot Study of Novel Topical Drug (Photocil) for the Treatment of Vitiligo
Status: Enrolling
Updated: 2/12/2016
Physicians Institute
mi
from
Tucson, AZ
Click here to add this to my saved trials
Efficacy and Safety of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
Lynchburg, VA
Efficacy and Safety of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
Lynchburg, VA
Click here to add this to my saved trials
Combination Therapy With Differin® Gel 0.3% and Duac® (Clindamycin/Benzoyl Peroxide Gel) in Subjects With Acne Vulgaris
A Clinical Assessment of Combination Therapy With Differin® Gel, 0.3% With Duac® (Clindamycin/Benzoyl Peroxide Gel) in Subjects With Acne Vulgaris
Status: Enrolling
Updated:  2/16/2016
Center for Dermatology & Laser Surgery
mi
from
Sacramento, CA
Combination Therapy With Differin® Gel 0.3% and Duac® (Clindamycin/Benzoyl Peroxide Gel) in Subjects With Acne Vulgaris
A Clinical Assessment of Combination Therapy With Differin® Gel, 0.3% With Duac® (Clindamycin/Benzoyl Peroxide Gel) in Subjects With Acne Vulgaris
Status: Enrolling
Updated: 2/16/2016
Center for Dermatology & Laser Surgery
mi
from
Sacramento, CA
Click here to add this to my saved trials
Combination Therapy With Differin® Gel 0.3% and Duac® (Clindamycin/Benzoyl Peroxide Gel) in Subjects With Acne Vulgaris
A Clinical Assessment of Combination Therapy With Differin® Gel, 0.3% With Duac® (Clindamycin/Benzoyl Peroxide Gel) in Subjects With Acne Vulgaris
Status: Enrolling
Updated:  2/16/2016
Derm Research, LLC
mi
from
Louisville, KY
Combination Therapy With Differin® Gel 0.3% and Duac® (Clindamycin/Benzoyl Peroxide Gel) in Subjects With Acne Vulgaris
A Clinical Assessment of Combination Therapy With Differin® Gel, 0.3% With Duac® (Clindamycin/Benzoyl Peroxide Gel) in Subjects With Acne Vulgaris
Status: Enrolling
Updated: 2/16/2016
Derm Research, LLC
mi
from
Louisville, KY
Click here to add this to my saved trials
Combination Therapy With Differin® Gel 0.3% and Duac® (Clindamycin/Benzoyl Peroxide Gel) in Subjects With Acne Vulgaris
A Clinical Assessment of Combination Therapy With Differin® Gel, 0.3% With Duac® (Clindamycin/Benzoyl Peroxide Gel) in Subjects With Acne Vulgaris
Status: Enrolling
Updated:  2/16/2016
Brodell Medical, Inc
mi
from
Warren, OH
Combination Therapy With Differin® Gel 0.3% and Duac® (Clindamycin/Benzoyl Peroxide Gel) in Subjects With Acne Vulgaris
A Clinical Assessment of Combination Therapy With Differin® Gel, 0.3% With Duac® (Clindamycin/Benzoyl Peroxide Gel) in Subjects With Acne Vulgaris
Status: Enrolling
Updated: 2/16/2016
Brodell Medical, Inc
mi
from
Warren, OH
Click here to add this to my saved trials
Combination Therapy With Differin® Gel 0.3% and Duac® (Clindamycin/Benzoyl Peroxide Gel) in Subjects With Acne Vulgaris
A Clinical Assessment of Combination Therapy With Differin® Gel, 0.3% With Duac® (Clindamycin/Benzoyl Peroxide Gel) in Subjects With Acne Vulgaris
Status: Enrolling
Updated:  2/16/2016
Northwest Cutaneous Research Specialists
mi
from
Portland, OR
Combination Therapy With Differin® Gel 0.3% and Duac® (Clindamycin/Benzoyl Peroxide Gel) in Subjects With Acne Vulgaris
A Clinical Assessment of Combination Therapy With Differin® Gel, 0.3% With Duac® (Clindamycin/Benzoyl Peroxide Gel) in Subjects With Acne Vulgaris
Status: Enrolling
Updated: 2/16/2016
Northwest Cutaneous Research Specialists
mi
from
Portland, OR
Click here to add this to my saved trials
Adapalene BPO Gel Pump, Moisturizer SPF 30 and Foam Wash in Patients With Mild to Moderate Acne Vulgaris
Epiduo® (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% Pump Cetaphil® DermaControl™ Moisturizer SPF 30, and Cetaphil® DermaControl™ Foaming Wash Regimen in Patients With Mild to Moderate Acne Vulgaris
Status: Enrolling
Updated:  2/17/2016
Study Protocol, Inc.
mi
from
Boynton Beach, FL
Adapalene BPO Gel Pump, Moisturizer SPF 30 and Foam Wash in Patients With Mild to Moderate Acne Vulgaris
Epiduo® (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% Pump Cetaphil® DermaControl™ Moisturizer SPF 30, and Cetaphil® DermaControl™ Foaming Wash Regimen in Patients With Mild to Moderate Acne Vulgaris
Status: Enrolling
Updated: 2/17/2016
Study Protocol, Inc.
mi
from
Boynton Beach, FL
Click here to add this to my saved trials
Adapalene BPO Gel Pump, Moisturizer SPF 30 and Foam Wash in Patients With Mild to Moderate Acne Vulgaris
Epiduo® (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% Pump Cetaphil® DermaControl™ Moisturizer SPF 30, and Cetaphil® DermaControl™ Foaming Wash Regimen in Patients With Mild to Moderate Acne Vulgaris
Status: Enrolling
Updated:  2/17/2016
Tennessee Clinical Research Center
mi
from
Nashville, TN
Adapalene BPO Gel Pump, Moisturizer SPF 30 and Foam Wash in Patients With Mild to Moderate Acne Vulgaris
Epiduo® (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% Pump Cetaphil® DermaControl™ Moisturizer SPF 30, and Cetaphil® DermaControl™ Foaming Wash Regimen in Patients With Mild to Moderate Acne Vulgaris
Status: Enrolling
Updated: 2/17/2016
Tennessee Clinical Research Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Adapalene BPO Gel Pump, Moisturizer SPF 30 and Foam Wash in Patients With Mild to Moderate Acne Vulgaris
Epiduo® (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% Pump Cetaphil® DermaControl™ Moisturizer SPF 30, and Cetaphil® DermaControl™ Foaming Wash Regimen in Patients With Mild to Moderate Acne Vulgaris
Status: Enrolling
Updated:  2/17/2016
Stephens & Associates
mi
from
Carrolton, TX
Adapalene BPO Gel Pump, Moisturizer SPF 30 and Foam Wash in Patients With Mild to Moderate Acne Vulgaris
Epiduo® (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% Pump Cetaphil® DermaControl™ Moisturizer SPF 30, and Cetaphil® DermaControl™ Foaming Wash Regimen in Patients With Mild to Moderate Acne Vulgaris
Status: Enrolling
Updated: 2/17/2016
Stephens & Associates
mi
from
Carrolton, TX
Click here to add this to my saved trials
Adapalene BPO Gel Pump, Moisturizer SPF 30 and Foam Wash in Patients With Mild to Moderate Acne Vulgaris
Epiduo® (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% Pump Cetaphil® DermaControl™ Moisturizer SPF 30, and Cetaphil® DermaControl™ Foaming Wash Regimen in Patients With Mild to Moderate Acne Vulgaris
Status: Enrolling
Updated:  2/17/2016
J&S Studies
mi
from
College Station, TX
Adapalene BPO Gel Pump, Moisturizer SPF 30 and Foam Wash in Patients With Mild to Moderate Acne Vulgaris
Epiduo® (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% Pump Cetaphil® DermaControl™ Moisturizer SPF 30, and Cetaphil® DermaControl™ Foaming Wash Regimen in Patients With Mild to Moderate Acne Vulgaris
Status: Enrolling
Updated: 2/17/2016
J&S Studies
mi
from
College Station, TX
Click here to add this to my saved trials
Adapalene BPO Gel Pump, Moisturizer SPF 30 and Foam Wash in Patients With Mild to Moderate Acne Vulgaris
Epiduo® (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% Pump Cetaphil® DermaControl™ Moisturizer SPF 30, and Cetaphil® DermaControl™ Foaming Wash Regimen in Patients With Mild to Moderate Acne Vulgaris
Status: Enrolling
Updated:  2/17/2016
The Dermatology Clinical Research Center of San Antonio
mi
from
San Antoinio, TX
Adapalene BPO Gel Pump, Moisturizer SPF 30 and Foam Wash in Patients With Mild to Moderate Acne Vulgaris
Epiduo® (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% Pump Cetaphil® DermaControl™ Moisturizer SPF 30, and Cetaphil® DermaControl™ Foaming Wash Regimen in Patients With Mild to Moderate Acne Vulgaris
Status: Enrolling
Updated: 2/17/2016
The Dermatology Clinical Research Center of San Antonio
mi
from
San Antoinio, TX
Click here to add this to my saved trials
Microneedling Plus the Universal Peel For Acne Scarring
Efficacy of Combination Therapy With Microneedling and the Universal Peel For Acne Scarring in Skin Types III-VI
Status: Enrolling
Updated:  2/18/2016
Bergen Dermatology
mi
from
Englewood Cliffs, NJ
Microneedling Plus the Universal Peel For Acne Scarring
Efficacy of Combination Therapy With Microneedling and the Universal Peel For Acne Scarring in Skin Types III-VI
Status: Enrolling
Updated: 2/18/2016
Bergen Dermatology
mi
from
Englewood Cliffs, NJ
Click here to add this to my saved trials
Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
Randomized, Multicentric, Controlled Study on the Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
Status: Enrolling
Updated:  2/23/2016
Hamzavi Dermatology/Dermatology Specialists of Canton
mi
from
Canton, MI
Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
Randomized, Multicentric, Controlled Study on the Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
Status: Enrolling
Updated: 2/23/2016
Hamzavi Dermatology/Dermatology Specialists of Canton
mi
from
Canton, MI
Click here to add this to my saved trials
Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
Randomized, Multicentric, Controlled Study on the Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
Status: Enrolling
Updated:  2/23/2016
Hamzavi Dermatology
mi
from
Fort Gratiot, MI
Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
Randomized, Multicentric, Controlled Study on the Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
Status: Enrolling
Updated: 2/23/2016
Hamzavi Dermatology
mi
from
Fort Gratiot, MI
Click here to add this to my saved trials
Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
Randomized, Multicentric, Controlled Study on the Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
Status: Enrolling
Updated:  2/23/2016
Lynderm Research
mi
from
Markham,
Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
Randomized, Multicentric, Controlled Study on the Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
Status: Enrolling
Updated: 2/23/2016
Lynderm Research
mi
from
Markham,
Click here to add this to my saved trials
A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA)
Status: Enrolling
Updated:  2/23/2016
Clinical Research Facility
mi
from
Fridley, MN
A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA)
Status: Enrolling
Updated: 2/23/2016
Clinical Research Facility
mi
from
Fridley, MN
Click here to add this to my saved trials
Photocil (Topical) for the Treatment of Atopic Dermatitis
Pilot Study of Novel Topical Drug (Photocil) for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  2/25/2016
Physicians Institute
mi
from
Tucson, AZ
Photocil (Topical) for the Treatment of Atopic Dermatitis
Pilot Study of Novel Topical Drug (Photocil) for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 2/25/2016
Physicians Institute
mi
from
Tucson, AZ
Click here to add this to my saved trials
Proof of Biological Activity of SAR100842 in Systemic Sclerosis
Double-blind, Randomized, 8-week Placebo-controlled, and 16-week Open-label Extension Study Investigating the Safety, Pharmacokinetics and Pharmacodynamics of SAR100842 Given Orally to Patients With Diffuse Cutaneous Systemic Sclerosis
Status: Enrolling
Updated:  2/26/2016
Clinical Research Facility
mi
from
Scottsdale, AZ
Proof of Biological Activity of SAR100842 in Systemic Sclerosis
Double-blind, Randomized, 8-week Placebo-controlled, and 16-week Open-label Extension Study Investigating the Safety, Pharmacokinetics and Pharmacodynamics of SAR100842 Given Orally to Patients With Diffuse Cutaneous Systemic Sclerosis
Status: Enrolling
Updated: 2/26/2016
Clinical Research Facility
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Proof of Biological Activity of SAR100842 in Systemic Sclerosis
Double-blind, Randomized, 8-week Placebo-controlled, and 16-week Open-label Extension Study Investigating the Safety, Pharmacokinetics and Pharmacodynamics of SAR100842 Given Orally to Patients With Diffuse Cutaneous Systemic Sclerosis
Status: Enrolling
Updated:  2/26/2016
Clinical Research Facility
mi
from
Washington,
Proof of Biological Activity of SAR100842 in Systemic Sclerosis
Double-blind, Randomized, 8-week Placebo-controlled, and 16-week Open-label Extension Study Investigating the Safety, Pharmacokinetics and Pharmacodynamics of SAR100842 Given Orally to Patients With Diffuse Cutaneous Systemic Sclerosis
Status: Enrolling
Updated: 2/26/2016
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
Proof of Biological Activity of SAR100842 in Systemic Sclerosis
Double-blind, Randomized, 8-week Placebo-controlled, and 16-week Open-label Extension Study Investigating the Safety, Pharmacokinetics and Pharmacodynamics of SAR100842 Given Orally to Patients With Diffuse Cutaneous Systemic Sclerosis
Status: Enrolling
Updated:  2/26/2016
Clinical Research Facility
mi
from
Baltimore, MD
Proof of Biological Activity of SAR100842 in Systemic Sclerosis
Double-blind, Randomized, 8-week Placebo-controlled, and 16-week Open-label Extension Study Investigating the Safety, Pharmacokinetics and Pharmacodynamics of SAR100842 Given Orally to Patients With Diffuse Cutaneous Systemic Sclerosis
Status: Enrolling
Updated: 2/26/2016
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Proof of Biological Activity of SAR100842 in Systemic Sclerosis
Double-blind, Randomized, 8-week Placebo-controlled, and 16-week Open-label Extension Study Investigating the Safety, Pharmacokinetics and Pharmacodynamics of SAR100842 Given Orally to Patients With Diffuse Cutaneous Systemic Sclerosis
Status: Enrolling
Updated:  2/26/2016
Clinical Research Facility
mi
from
Boston, MA
Proof of Biological Activity of SAR100842 in Systemic Sclerosis
Double-blind, Randomized, 8-week Placebo-controlled, and 16-week Open-label Extension Study Investigating the Safety, Pharmacokinetics and Pharmacodynamics of SAR100842 Given Orally to Patients With Diffuse Cutaneous Systemic Sclerosis
Status: Enrolling
Updated: 2/26/2016
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Proof of Biological Activity of SAR100842 in Systemic Sclerosis
Double-blind, Randomized, 8-week Placebo-controlled, and 16-week Open-label Extension Study Investigating the Safety, Pharmacokinetics and Pharmacodynamics of SAR100842 Given Orally to Patients With Diffuse Cutaneous Systemic Sclerosis
Status: Enrolling
Updated:  2/26/2016
Clinical Research Facility
mi
from
Ann Arbor, MI
Proof of Biological Activity of SAR100842 in Systemic Sclerosis
Double-blind, Randomized, 8-week Placebo-controlled, and 16-week Open-label Extension Study Investigating the Safety, Pharmacokinetics and Pharmacodynamics of SAR100842 Given Orally to Patients With Diffuse Cutaneous Systemic Sclerosis
Status: Enrolling
Updated: 2/26/2016
Clinical Research Facility
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Proof of Biological Activity of SAR100842 in Systemic Sclerosis
Double-blind, Randomized, 8-week Placebo-controlled, and 16-week Open-label Extension Study Investigating the Safety, Pharmacokinetics and Pharmacodynamics of SAR100842 Given Orally to Patients With Diffuse Cutaneous Systemic Sclerosis
Status: Enrolling
Updated:  2/26/2016
Clinical Research Facility
mi
from
New Brunswick, NJ
Proof of Biological Activity of SAR100842 in Systemic Sclerosis
Double-blind, Randomized, 8-week Placebo-controlled, and 16-week Open-label Extension Study Investigating the Safety, Pharmacokinetics and Pharmacodynamics of SAR100842 Given Orally to Patients With Diffuse Cutaneous Systemic Sclerosis
Status: Enrolling
Updated: 2/26/2016
Clinical Research Facility
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Proof of Biological Activity of SAR100842 in Systemic Sclerosis
Double-blind, Randomized, 8-week Placebo-controlled, and 16-week Open-label Extension Study Investigating the Safety, Pharmacokinetics and Pharmacodynamics of SAR100842 Given Orally to Patients With Diffuse Cutaneous Systemic Sclerosis
Status: Enrolling
Updated:  2/26/2016
Clinical Research Facility
mi
from
Pittsburgh, PA
Proof of Biological Activity of SAR100842 in Systemic Sclerosis
Double-blind, Randomized, 8-week Placebo-controlled, and 16-week Open-label Extension Study Investigating the Safety, Pharmacokinetics and Pharmacodynamics of SAR100842 Given Orally to Patients With Diffuse Cutaneous Systemic Sclerosis
Status: Enrolling
Updated: 2/26/2016
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Proof of Biological Activity of SAR100842 in Systemic Sclerosis
Double-blind, Randomized, 8-week Placebo-controlled, and 16-week Open-label Extension Study Investigating the Safety, Pharmacokinetics and Pharmacodynamics of SAR100842 Given Orally to Patients With Diffuse Cutaneous Systemic Sclerosis
Status: Enrolling
Updated:  2/26/2016
mi
from
Lille,
Proof of Biological Activity of SAR100842 in Systemic Sclerosis
Double-blind, Randomized, 8-week Placebo-controlled, and 16-week Open-label Extension Study Investigating the Safety, Pharmacokinetics and Pharmacodynamics of SAR100842 Given Orally to Patients With Diffuse Cutaneous Systemic Sclerosis
Status: Enrolling
Updated: 2/26/2016
mi
from
Lille,
Click here to add this to my saved trials
Study to Evaluate Effect of Pandel Cream 0.1% on HPA Axis in Pediatric and Adult Population
An Open -Label Study to Evaluate the Effect of Pandel Cream 0.1% on the Hypothalamic Pituitary Adrenal Axis in the Pediatric and Adult Population
Status: Enrolling
Updated:  2/26/2016
Christopher Huerter, MD
mi
from
Omaha, NE
Study to Evaluate Effect of Pandel Cream 0.1% on HPA Axis in Pediatric and Adult Population
An Open -Label Study to Evaluate the Effect of Pandel Cream 0.1% on the Hypothalamic Pituitary Adrenal Axis in the Pediatric and Adult Population
Status: Enrolling
Updated: 2/26/2016
Christopher Huerter, MD
mi
from
Omaha, NE
Click here to add this to my saved trials
Study to Evaluate Effect of Pandel Cream 0.1% on HPA Axis in Pediatric and Adult Population
An Open -Label Study to Evaluate the Effect of Pandel Cream 0.1% on the Hypothalamic Pituitary Adrenal Axis in the Pediatric and Adult Population
Status: Enrolling
Updated:  2/26/2016
Oswald Mikell, MD
mi
from
Hilton Head Island, SC
Study to Evaluate Effect of Pandel Cream 0.1% on HPA Axis in Pediatric and Adult Population
An Open -Label Study to Evaluate the Effect of Pandel Cream 0.1% on the Hypothalamic Pituitary Adrenal Axis in the Pediatric and Adult Population
Status: Enrolling
Updated: 2/26/2016
Oswald Mikell, MD
mi
from
Hilton Head Island, SC
Click here to add this to my saved trials
Study to Evaluate Effect of Pandel Cream 0.1% on HPA Axis in Pediatric and Adult Population
An Open -Label Study to Evaluate the Effect of Pandel Cream 0.1% on the Hypothalamic Pituitary Adrenal Axis in the Pediatric and Adult Population
Status: Enrolling
Updated:  2/26/2016
Michael Gold, MD
mi
from
Nashville, TN
Study to Evaluate Effect of Pandel Cream 0.1% on HPA Axis in Pediatric and Adult Population
An Open -Label Study to Evaluate the Effect of Pandel Cream 0.1% on the Hypothalamic Pituitary Adrenal Axis in the Pediatric and Adult Population
Status: Enrolling
Updated: 2/26/2016
Michael Gold, MD
mi
from
Nashville, TN
Click here to add this to my saved trials
ALC-919 For The Treatment Of Common Warts
ALC-919 For The Treatment Of Common Warts (Verruca Vulgaris)
Status: Enrolling
Updated:  3/8/2016
Philadelphia Institute of Dermatology
mi
from
Fort Washington, PA
ALC-919 For The Treatment Of Common Warts
ALC-919 For The Treatment Of Common Warts (Verruca Vulgaris)
Status: Enrolling
Updated: 3/8/2016
Philadelphia Institute of Dermatology
mi
from
Fort Washington, PA
Click here to add this to my saved trials
Thalidomide for Decreasing Collagen Biosynthesis in People With Progressive Systemic Sclerosis
T Cell Immunity in Collagen Biosynthesis of Scleroderma
Status: Enrolling
Updated:  3/10/2016
New York University School of Medicine General Clinical Research Center, Bellevue Hospital
mi
from
New York, NY
Thalidomide for Decreasing Collagen Biosynthesis in People With Progressive Systemic Sclerosis
T Cell Immunity in Collagen Biosynthesis of Scleroderma
Status: Enrolling
Updated: 3/10/2016
New York University School of Medicine General Clinical Research Center, Bellevue Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis
Status: Enrolling
Updated:  3/14/2016
Anacor Investigational Site
mi
from
Stockbridge, GA
Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis
Status: Enrolling
Updated: 3/14/2016
Anacor Investigational Site
mi
from
Stockbridge, GA
Click here to add this to my saved trials
Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Aged 2 Years and Older) With Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis
Status: Enrolling
Updated:  3/14/2016
Anacor Investigational Site
mi
from
Henrico, VA
Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Aged 2 Years and Older) With Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis
Status: Enrolling
Updated: 3/14/2016
Anacor Investigational Site
mi
from
Henrico, VA
Click here to add this to my saved trials
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  3/14/2016
Local Institution
mi
from
Scottsdale, AZ
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 3/14/2016
Local Institution
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  3/14/2016
Local Institution
mi
from
Los Angeles, CA
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 3/14/2016
Local Institution
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  3/14/2016
Local Institution
mi
from
Stanford, CA
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 3/14/2016
Local Institution
mi
from
Stanford, CA
Click here to add this to my saved trials
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  3/14/2016
Local Institution
mi
from
Aurora, CO
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 3/14/2016
Local Institution
mi
from
Aurora, CO
Click here to add this to my saved trials
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  3/14/2016
Local Institution
mi
from
Washington,
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 3/14/2016
Local Institution
mi
from
Washington,
Click here to add this to my saved trials
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  3/14/2016
Local Institution
mi
from
Washington,
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 3/14/2016
Local Institution
mi
from
Washington,
Click here to add this to my saved trials
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  3/14/2016
Local Institution
mi
from
Chicago, IL
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 3/14/2016
Local Institution
mi
from
Chicago, IL
Click here to add this to my saved trials
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  3/14/2016
Local Institution
mi
from
Baltimore, MD
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 3/14/2016
Local Institution
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  3/14/2016
Local Institution
mi
from
Boston, MA
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 3/14/2016
Local Institution
mi
from
Boston, MA
Click here to add this to my saved trials
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  3/14/2016
Local Institution
mi
from
Boston, MA
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 3/14/2016
Local Institution
mi
from
Boston, MA
Click here to add this to my saved trials